Delphia (USA)’s CytomX Therapeutics CTMX Stock Holding History

Delphia (USA)’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,630	Closed	-$39K	–	410
2022 Q1	$39K	Buy	+14,630	New	+$56.2K	0.03%	323

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Delphia (USA)'s CTMX Position: Q2 2022 in Review

Delphia (USA) sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 14,630 shares — an estimated $39K sold.

Delphia (USA) first reported a position in CTMX in Q1 2022 and held it in 1 quarter. The position peaked at $39K in Q1 2022. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

Delphia (USA) reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
Delphia (USA) sold 14,630 CytomX Therapeutics shares in Q2 2022, an estimated $39K.
Delphia (USA) first reported a position in CytomX Therapeutics in Q1 2022 and held it in 1 quarter.
Delphia (USA)'s CytomX Therapeutics position peaked at $39K in Q1 2022.
98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.